• Travere Therapeutics priced an upsized USD 475 million offering of 0.50% convertible senior notes due 2032, increasing deal size from USD 400 million.
• Notes expected to close May 11, 2026; underwriters hold 30-day option to buy up to an additional USD 50 million to cover over-allotments.
• Net proceeds estimated at about USD 460 million, earmarking about USD 350.9 million to repurchase about USD 221.4 million principal amount of 2.25% senior convertible notes due 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260506765175) on May 07, 2026, and is solely responsible for the information contained therein.